Dr. Ikeguchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Unit 0430
Houston, TX 77030- Is this information wrong?
Summary
- Dr. Alexandra Ikeguchi is an oncologist in Houston, TX and is affiliated with UT MD Anderson Cancer Center. She received her medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 25 years. She specializes in melanoma and is experienced in squamous cell carcinoma, melanoma, mucosal melanoma, merkel cell carcinoma, and uveal neoplasms. She has 8 publications and over 50 citings.
Education & Training
- New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1995 - 1998
- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1992 - 1995
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1992
Certifications & Licensure
- FL State Medical License 2023 - Present
- TX State Medical License 2023 - 2026
- TN State Medical License 2023 - 2026
- GA State Medical License 2023 - 2025
- WA State Medical License 2023 - 2024
- AL State Medical License 2024 - 2024
- LA State Medical License 2023 - 2024
- American Board of Internal Medicine Hematology
- Join now to see all
Clinical Trials
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
- Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients Start of enrollment: 2012 Dec 01
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Dec 13
- Join now to see all
Publications & Presentations
PubMed
- A Bioinformatics Tool for Identifying Intratumoral Microbes from the ORIEN Dataset.Tinoco Suarez, G. R., Tinoco Suarez, G. R., Tinoco Suarez, G. R., Tinoco Suarez, G. R., Wang, C., Ma, A., Li, Y., McNutt, M., Zhang, S., Zhu, J., Hoyd, R., Wheeler, C....> ;Cancer Research Communications. 2024 Feb 5
- The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhib...Islam Eljilany, Payman Ghasemi Saghand, James Chen, Aakrosh Ratan, Martin McCarter, John Carpten, Howard Colman, Alexandra P Ikeguchi, Igor Puzanov, Susanne Arnold, Mi...> ;Cancers. 2023 Oct 10
- 1 citationsThe tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors.Caroline E Wheeler, Samuel S Coleman 4th, Rebecca Hoyd, Louis Denko, Carlos H F Chan, Michelle L Churchman, Nicholas Denko, Rebecca D Dodd, Islam Eljilany, Sheetal Har...> ;Biorxiv. 2023 May 25
- Join now to see all
Press Mentions
- ECOG-ACRIN Cancer Research Group Melanoma Research Team Led by Michael Atkins, MD, Receives the 2023 Paper of the Year Distinction from the Journal of Clinical OncologyJanuary 19th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: